|
1. BIOLOGIE
|
|
|
|
3.1.1 PRÉVENTION - TABAC - E-CIGS
|
|
|
NIH-funded study finds teens prefer mint and mango vaping flavors [NIH]
|
|
|
|
|
|
The study focused on JUUL products, the most widely used brand, which is available in multiple flavors. Data were from the 2019 Monitoring the Future (MTF) study, which annually surveys eighth, 10th, and 12th grade students in U.S. schools. A randomly-selected third of MTF respondents were asked, “Which JUUL flavor do you use most often?”
|
|
|
|
|
|
|
|
e-Cigarette Use Among Youth in the United States, 2019 [JAMA]
|
|
|
|
|
|
In 2019, the prevalence of self-reported e-cigarette use was high among high school and middle school students, with many current e-cigarette users reporting frequent use and most of the exclusive e-cigarette users reporting use of flavored e-cigarettes.
|
|
|
|
|
|
|
5.1 TRAITEMENTS - PRÉ-CLINIQUE
|
|
|
The advent and rise of monoclonal antibodies [Nature]
|
|
|
|
|
|
A 1975 Nature paper reported how cell lines could be made that produce an antibody of known specificity. This discovery led to major biological insights and clinical successes in treating autoimmunity and cancer.
|
|
|
|
|
|
|
5.12.1 IMMUNOTHÉRAPIES - PARTENARIATS
|
|
|
|
5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
|
|
|
|
5.12.4 IMMUNOTHÉRAPIES - ESSAIS
|
|
|
|
5.12.5 IMMUNOTHÉRAPIES - PHARMA
|
|
|
Regeneron defends bid to challenge Merck in lung cancer [Biopharma Dive]
|
|
|
|
|
|
How well Regeneron can do that will depend on success in studies like the two Phase 3 trials the biotech is running in first-line non-small cell lung cancer. An update shared by Regeneron on Tuesday revealed both studies to be enrolling quickly, with potential results forthcoming next year for the first.
|
|
|
|
|
|
|
5.2.1 PHARMA - PARTENARIATS
|
|
|
|
5.2.3 PHARMA - ÉCONOMIE
|
|
|
|
|
5.2.6 PHARMA - BIOTECH
|
|
|
|
5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
|
|
|
|
|
|
|
6.1 OBSERVATION
|
|
|
|
6.6 PUBLICATIONS
|
|
|
|
6.7.1 IA/BIOINFORMATIQUE
|
|
|